- Current report filing (8-K)

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

__________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):   May 29, 2009

THE FEMALE HEALTH COMPANY

(Exact name of registrant as specified in its charter)

Wisconsin

(State or other jurisdiction of incorporation)

1-13602		39-1144397
(Commission File Number)		(I.R.S. Employer I.D. Number)

515 North State Street Suite 2225 Chicago, Illinois		60654
(Address of Principal Executive Offices)		(Zip Code)

312-595-9123

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

           

 

 

---

 

Section 3 – Securities and Trading Markets

Item 3.01  Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On May 29,2009, the Board of Directors of The Female Health Company (the "Company") approved the transfer of the listing of the Company's common stock to the NASDAQ Stock Market LLC ("NASDAQ") from NYSE Amex LLC ("AMEX") and authorized the Company's management to take all necessary action to effect the listing and trading of the common stock on NASDAQ and the delisting of the common stock from AMEX and the suspension of its trading thereon.

The Company expects that its common stock will cease trading on AMEX at the close of the market on June 8, 2009 and will commence trading on NASDAQ at the opening of the market on June 9, 2009.

 

2

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE FEMALE HEALTH COMPANY

Date:  May 29, 2009

BY /s/ Donna Felch                                               

      Donna Felch, Vice President and  

      Chief Financial Officer

 

3

---